Prevention and early treatment of influenza in healthy adults

Vaccine

Volumn 18, Issue 11-12, 2000, Pages 957-1030

  Demicheli, V ^a   Jefferson, T ^b   Rivetti, D ^c   Deeks, J ^d  

^a UNIVERSITY OF PAVIA   (Italy)

^b UK COCHRANE CENTRE   (United Kingdom)

^c ARPA   (Italy)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; INFLUENZA VACCINE; OSELTAMIVIR; RIMANTADINE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; INTRANASAL DRUG ADMINISTRATION; META ANALYSIS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 0033991487     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00332-1     Document Type: Review

References (37)

1. Wiselka M. Influenza: diagnosis, management and prophylaxis. BMJ. 308:1994;1341-1345.
2. Bonn D. Spared an influenza pandemic for another year? Lancet. 349:1997;36.
3. Belshe R.B. Influenza as a zoonosis: how likely is a pandemic? Lancet. 351:1998;460-461.
4. Yuen K.Y., Chan P.K.S., Peiris M., et al. Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet. 351:1998;467-471.
5. Claas E.C., Osterhaus A.D.M., van Beek R., et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet. 351:1998;472-477.
6. Jefferson T.O., Demicheli V. The socioeconomics of influenza. Nicholson, Hay, Webster. Textbook of Influenza. 1998;541-547 Blackwell, London.
7. World Health Organisation (WHO). International list of availability of vaccines and sera. Fourth edition. Geneva 1996 (updated February).
8. McDowell I., Newell C., Rosser W. Comparison of three methods of recalling patients for influenza vaccination. Can. Med. Assoc. J. 135:1986;991-997.
9. Lukasik M.H., Pratt G. The telephone: an overlooked technology for prevention in family medicine. Can. Fam. Physician. 33:1987;1997-2021.
10. Gerace T.M., Sangster J.F. Influenza vaccination: a comparison of two outreach strategies. Fam. Med. 20:1988;43-45.
11. Prevention and control of influenza. MMWR. 47:(3 no RR-6):1998.
12. Gross P.A., Hermogenes A.W., Sacks H.S., et al. The efficacy of influenza vaccines in elderly people: A meta-analysis and review of the literature. Annals of Internal Medicine. 123:1995;518-527.
13. Strassburg M.A., Greenland S., Sorvillo F.J., et al. Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports. Vaccine. 4:1986;38-44.
14. Couch R. Summary of medical literature review of effectiveness of inactivated influenza virus vaccines. Cost Effectiveness of Influenza Vaccination. 1981;43-45 Office of Technology Assessment, Washington.
15. Hobson D. Assessment of the efficacy of influenza vaccines against natural challenge. Develop. Biol. Standard. 28:1975;285-294.
16. Prevention and control of influenza. MMWR. 37:1988;361-373.
17. Prevention and control of influenza. MMWR. 47:(3 no RR-6.):1998.
18. Prevention and control of influenza: Part II, antiviral agents. MMWR. 43:1994;1-9.
19. Loughlin C.A. The discovery and development of therapies for influenza infections. Hannoun C., et al. Options for the control of influenza. 1993;327-331 Elsevier, Amsterdam.
20. Hayden F.G., Couch R.B. Clinical and epidemiological importance of influenza A viruses resistant to amantadine and rimantadine. Hannoun C., et al. Options for the control of influenza. 1993;333-342 Elsevier, Amsterdam.
21. Wintermeyer S.M., Nahata M.C. Rimantadine: a clinical perspective. The Annals of Pharmacotherapy. 29:1995;299-310.
22. Penn C.R. Inhibitors of influenza virus neuraminidase. Nicholson K.G., Hay R.G., Webster A.J. Textbook of Influenza. 1998;477-487 Blackwell, London. (Chapter 36).
23. Couch R.B. A new antiviral agent for influenza: Is there a clinical niche? New England Journal of Medicine. 337:1997;927-928. (editorial).
24. Pfeiffer N. Firms racing to develop drugs for influenza virus. Genetic Engineering News. 17:(1 November):1997;1-16.
25. Wright L.A., Demicheli V., Gillespie W., Jefferson T.O. Morbidity surveillance in the British Army - the first 12 months. J. R. Army Med. Corps. 144:1998;11-17.
26. McMenamin J., Morton R., McEwen J. Report of a pilot programme of enhanced surveillance of respiratory illness in the British Army (UK). 1998;University of Glasgow, Department of Public Health.
27. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Influenza vaccines in healthy adults. Cochrane Database of Systematic Reviews (Acute Respiratory Infections Module). Update Software 1999 (forthcoming).
28. Jefferson TO, Demicheli V, Deeks JJ, Rivetti D. Amantadine & rimantadine for influenza. Cochrane Database of Systematic Reviews (Acute Respiratory Infections Module). Update Software 1999, issue 2.
29. Jefferson TO, Demicheli V, Deeks JJ, Rivetti D. Neuraminidase inhibitors for influenza. Cochrane Database of Systematic Reviews (Acute Respiratory Infections Module). Update Software 1999, issue 2.
30. Drummond M.F., Donaldson C., Jönsson B., Mugford M., Rennie D., Rovira J., Rutten F., Schulman K., Smith R., Tonks A., Torrance G., Towse A. Guidelines for authors and peer-reviewers of economic submissions to the British Medical Journal. BMJ. 313:(3 August):1996;275-283.
31. Cochrane Acute Respiratory Infections Group. Search strategy for specialised register. Cochrane Library 1998 Issue 1. Oxford: Update Software (updated quarterly).
32. Jefferson T.O., Jefferson V.M. The quest for trials on the efficacy of human vaccines. Results of the handsearch of 'Vaccine'. Vaccine. 14:1996;461-464.
33. Jefferson T.O. Vaccine trial data systematically assembled, pooled and disseminated by the Cochrane Collaboration. Vaccine. 16:1998;1487-1495.
34. Schulz K.F., Chalmers I., Hayes R.J., Altman D.G. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 273:1995;408-412.
35. Jefferson T.O. Demicheli V. Economic evaluation of Influenza vaccination and economic modelling. Can results be pooled? Pharmacoeconomics. 9:(Suppl 3):1996;67-72.
36. Jefferson T.O., Demicheli V. A systematic review of world literature on the economics of influenza. Information and News on Influenza. European Scientific Working Group on Influenza (Newsletter). 7:1997;6.
37. Aoki F.Y. Amantadine and rimantadine. Nicholson K.G., Hay A.J., Webster R.G. Textbook of Influenza. 1998;457-476 Blackwell, London.